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treated with double antiplatelet therapy for 3 months. Results angiographic success was 
obtained in all cases. During the hospital there were no death or repeat revasculariza- 
tions. Non Q-wave myocardial infarction (MI) occurred in 2 (2%) cases in the control arm 
(p=n.s.). After 1 months, no patient died. One patients in the estrogen arm had a non-Q 
wave MI 3 days after the procedure and target lesion revascularization with re-PTCA was 
repeated. All the patients have been scheduled for a 6-month angiographic FU that will 
be available at the time of presentation.Conclusions Stenting lesions on native coronary 
arteries with the estrogen coated stents is safe and is associated with high procedural 
success rate. In hospital course and i-month FU Indicate that estrogen coating stents do 
not seem to increase the risk of acute or sub-acute stent thrombosis compared to bare 
metal stent. The efficacy of this therapy in reducing restenosis rate will be assessed 
when the 6-months angiographic FU results will be available. 
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Potential drugs for vascular delivery have variable kinetic release requirements. Some 
first generation drug eluting stents have utilized non-erodable polymers and fixed kinet- 
ics, which may be responsible for late malapposition and restenosis. Bioerodable poly- 
mers positioned within the volume of a stent strut may be metabolized without tissue 
toxicity or malapposition. We evaluated configurations of the Conor stent with differing 
polymer volumes and degradation rates for restenosis and tissue toxicity. 
Methods and Results: The Conor stew has honey-combed metallic strut elements that 
contain automated programmable inlaid layers of bioerodable Polylactide-co-glycolide 
(PLGA). Degradation rates were manipulated by altering the PLGA co-monomer ratio 
and molecular weight. Three low volume PLGA groups with different in-vitrodegradation 
rates (21 to 180 days), one high volume PLGA group (21 days), and bare metal stent 
controls were randomly implanted !n the LAD, RCA and superficial femoral arteries (n=40 
stents) in a 30 day porcine model (n=12 pigs). Mean coronary injury scores (range: 1.1 to 
1.4) did not differ between the five groups. Tissue sections preserving metal and polymer 
architecture showed small but significant differences in polymer degradation rate (89% 
vs 78% in fast vs slow groups, pcO.05). Increasing the polymer volume 4-fold slowed the 
degradation rate to near zero. Blinded histologic scoring showed a neoendothelium, min- 
imal inflammation, foreign body reaction or neointimal fibrin and complete healing in all 
groups. NO medial necrws or stent strut malapposition was seen. Quantitative angiogra- 
phy and histomorphometry showed no difference in restenosis parameters versus bare 
metal controls. 
6ackground:The ISAR-STEREO-2 tnal has shown that stent strut thickness has a sig- 
nificant Impact on long-term outcome, with lower restenosis rates for thinner strut stents. 
This effect was seen in a comparison of 2 stents with different design, the thin-strut 
Guidant RX MultiLink and the thick-strut Cordis 8X Veloccty Small vessels (<2.8mm) 
have higher restenosis rates, and although some trials in small vessels have shown a 
significantly lower restenosis rate after stenting compared to PTCA, others have failed to 
show such benefit, including the ISAR-SMART trial using the MultiLink. Goal of the 
present analysis was therefore to differentlate the results of ISAR-STEREO-2 with 
respect to vessel size. 
Methods: All 611 patients randomized I” ISAR-STEREO-2 were included in this analy- 
sis. Results for patients with target vessels <2.8mm (n=262) were compared to those 
with large vessels (Z2.8mm; n=349). 
Results: Baseline clinical and angiographic characteristics did not differ significantly 
between the 2 groups. The primary end point of ISAR-STEREO-E, angiographic resteno- 
sis rate at 6 mo., is illustrated in the graph. 
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Conclusions: PLGA degradation rates are controllable but very less than predlcted in- 
vitro and are volume dependent. Erodable PLGA polymers positioned within the steni 
struts are non toxic and suitable for the controlled elution of bioactive substances. 
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Background: Coronary stent surface modification can improve the biocompatibility of a 
stent. Nrtroxides have shown a wide range of biological effects like suppressing free rad- 
ical driven reactions to maintain cell functions. The objectives of this study was to evalu- 
ate the efficacy of a biodegradable polymer coated stent loaded with nitroxyl groups on 
in-stent neomtimal hyperplasia. 
Methods: Bare stainless steel stents (Genie stents, Blue Medical Devices, The Nether- 
lands), loaded 50% (W%) nitroxyl groups ( Tempo Amine, Blue Medical Devices, The 
Netherlands) biodegradable elastomeric poly(ester-amide)(co-PEA) polymer dipcoated 
stents and control polymer coated stents were randomly implanted into porcine coronary 
arteries. Arterial segments were selected to achieve a balloon to artery ratio 1.5-l .2:1. Al 
5 days (4 stents for each group) and 6 weeks (bare n=8, both polymer coated and 50% 
Tempo loaded stents n=16) follow-up, histomorphometric analysis was performed on 
proximal, middle and distal parl of each stent segment. 
Results: Histomorphometric analysis showed that the bare stems, polymer-coated stents 
and Tempo loaded stents elicited a stmilar tissue response at 5 days follow-up. At 6 
weeks follow-up, the peri-strut inflammation of the polymer coated stents (1.03+0.06 vs 
1.09+0.14, P<O.OS) and Tempo loaded stents(l.O2+0.05 vs 1.09*0.14, PcO.01) were 
significantly lower than the bare stents. Arterial injury of bare stents was significantly 
higher than the polymer coated stems (0.33eO.21 vs 0.62iO.46, PcO.01) and Tempo 
loaded stents (0.34+0.23 vs 0.62+0.46,P<O.O1). Compared to the bare stents, the neoin- 
timal hyperplasis. and area stenosis of polymer coated stents (1.41?0.61 vs 1.78kO.79 
mm2; 25+11 vs 35+23 %; PqO.05) and Tempo loaded stems (1.27t0.42 vs 1.78*0.79 
mm2; 24*8 vs 35+23 %; P<O.Ol) were significantly decreased. The neointimal hyperpla- 
sia of Tempo loaded stems was the lowest. 
Conclusion: These co-PEA polymer stent coating showed a biocompatible performance 
and could decrease the neointimal hyperplasia at 6 weeks follow-up compared to bare 
stents. Loading of the polymer wth nitroxyl groups could further suppress the neomtimal 
formation. 
Conclusions: This subgroup analysis of ISAR-STEREO-2 shows that restenosis rates 
of the thick-strut Velocity do not differ according to vessel size. The advantage the thin- 
strut stent in this trial, the MultiLink, is for the most part limited to large vessels. This anal- 
ysis suggests that beyond strut thickness, different stent design features may play a dif- 
ferent role dependent on vessel size. 
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The evolution of an “ideal” stent platform remains critically Important in the era of drug 
eluting stents. Stem strut thickness and alloy may influence device profile, flexibility, 
deliverability, vwbility and radial strength. A novel thin strut (0.0032”) cobalt chromium 
MULTI-LINK (Guidant Corporabon) VISIONTM stent (n=294; lengths 8, 12, 15, 18, 23,28 
mm; diameters 3.0, 3.5, 4.0 mm) was deployed in 267 pabents (age 64 years, 68% male, 
23% diabetes) with a single de now native target vessel lesion k 25 mm length) in a 
multi-center international registry. Anglographic and clinical outcomes for the MULTI- 
LINK VISIONTM stents are compared with those previously observed for the TETRATM 
and PENTATM MULTI-LINK@stents. 
Conclusiorx This novel thin strut cobalt chromium MULTI-LINK VISION TM stent demon- 
strates excellent clinical performance charactenstics with reduced late loss and resteno- 
sis compared with prior MULTI-LINK@ stents. 
